Protagenic Therapeutics, Inc.\new OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax
Protagenic Therapeutics, Inc.\new (PTIX) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax of $0 for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-14.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax · last filed 2020-08-14
- Protagenic Therapeutics, Inc.\new oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2020-06-30 was $0.00.
- Protagenic Therapeutics, Inc.\new oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2019-12-31 was $4.82K, a 62.68% decline year-over-year.
- Protagenic Therapeutics, Inc.\new oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2019-09-30 was -$4.82K.
- Protagenic Therapeutics, Inc.\new oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2019 was $4.82K, a 22.83% decline from fiscal 2018.
- Protagenic Therapeutics, Inc.\new oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2018 was $6.25K, a 337.98% increase from fiscal 2017.
- Protagenic Therapeutics, Inc.\new oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2017 was $1.43K.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 3 month as first filed | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 6 month as first filed | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 12 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $0.00 10-Q · filed 2020-08-14 | $4.82K derived: sum of 3 quarters · filed 2020-08-14 | $0.00 derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2020-03-31 | $0.00 10-Q · filed 2020-06-18 | $4.82K derived: sum of 2 quarters · filed 2020-06-18 | $0.00 derived: sum of 3 quarters · filed 2020-06-18 | $0.00 derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2019-12-31 | $4.82K derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-29 | $0.00 derived: sum of 2 quarters · filed 2020-04-29 | $0.00 derived: sum of 3 quarters · filed 2020-08-14 | $4.82K 10-K · filed 2020-04-29 | |||
| 2019-09-30 | -$4.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$4.82K derived: sum of 2 quarters · filed 2020-08-14 | $0.00 10-Q · filed 2019-11-14 | $12.92K derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $4.82K 10-Q · filed 2020-08-14 | $0.00 10-Q · filed 2019-08-14 | $17.75K derived: sum of 3 quarters · filed 2020-08-14 | $15.97K derived: sum of 4 quarters · filed 2020-08-14 | ||
| 2019-03-31 | $4.82K 10-Q · filed 2020-06-18 | $0.00 10-Q · filed 2019-05-16 | $17.75K derived: sum of 2 quarters · filed 2020-06-18 | $15.97K derived: sum of 3 quarters · filed 2020-06-18 | |||
| 2018-12-31 | $12.92K derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-29 | $11.14K derived: sum of 2 quarters · filed 2020-04-29 | $6.25K 10-K · filed 2020-04-29 | -$6.25K 10-K · filed 2019-03-29 | |||
| 2018-09-30 | -$1.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$6.67K 10-Q · filed 2018-11-08 | |||||
| 2018-06-30 | -$4.89K 10-Q · filed 2018-08-14 | ||||||
| 2017-12-31 | -$571.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | -$1.74K derived: sum of 2 quarters · filed 2019-03-29 | $1.43K 10-K · filed 2019-03-29 | ||||
| 2017-09-30 | -$1.17K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $2.00K 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | $3.16K 10-Q · filed 2018-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |